Nycomed Amersham Imaging has begun clinical testing of the first of several MRI agents to employ the firm's spin signal technology. The phase I trial for the agent, called NC100182, will study lung imaging, the company said.
The Princeton, NJ-based contrast agent developer hopes the agent will have applications for patients with asthma, cystic fibrosis, and chronic obstructive lung diseases such as emphysema, as well as patients undergoing transplantation and volume reduction surgery. In anticipation of successful completion of the phase I testing in the fall, the company is planning phase II trials to begin in early 2001.
By AuntMinnie.com staff writersAugust 23, 2000
Related Reading
Nycomed Amersham results climb in first half of 2000, August 8, 2000
Nycomed inks deal with Premier for prostate brachytherapy, August 3, 2000
Nycomed Amersham joins Global Healthcare Exchange, July 26, 2000
Contrast study favors Nycomed agent in coronary procedures, May 10, 2000
Nycomed and Mallinckrodt settle patent suits, May 8, 2000
Nycomed spotlights OncoSeed study, May 4, 2000
Copyright © 2000 AuntMinnie.com
